Viela Bio receives US FDA breakthrough therapy designation for Inebilizumab to treat Neuromyelitis Optica Spectrum Disorder
NMOSD is a rare, life-threatening autoimmune disease affecting the central nervous system. “The Breakthrough Therapy Designation for inebilizumab is based on results from the largest monotherapy study ever
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.